Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
BMT
acute leukaemia
breast cancer
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
31 Mar 2024
31 Mar 2024
Historique:
revised:
14
03
2024
received:
14
02
2024
accepted:
16
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Therapy-related acute lymphoblastic leukaemia (tr-ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr-ALL, likely due to high prevalence and excellent curable rate for non-metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse-free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr-ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr-ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, et al. Therapy‐related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103:1662–1668.
Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, et al. Therapy‐related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228–4237.
Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, et al. Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia. Br J Haematol. 2021;25:963–968.
Kelleher N, Gallardo D, Gonzalez‐Campos J, Hernández‐Rivas JM, Montesinos P, Sarrá J, et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leuk Lymphoma. 2016;57(1):86–91.
Ribera JM. Therapy‐related acute lymphoblastic leukemia. Haematologica. 2018;103(10):1581–1583.
Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy‐related myeloid neoplasms. Chem Biol Interact. 2010;184:39–45.
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.
Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, et al. High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia. Am J Hematol. 2022;97(5):E171–E173.
National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (Version 4.2023) [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
Aldoss I, Pullarkat V. Therapy‐related acute myeloid leukemia with favorable cytogenetics: still favorable? Leuk Res. 2012;36(12):1547–1551.
Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937–945.
Miao H, Verkooijen HM, Chia KS. Incidence and outcome of male breast cancer: an international population‐based study. J Clin Oncol. 2011;29(33):4381–4386.
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001‐2007. Blood. 2012;119(1):34–43.
Centers for Disease Control and Prevention. U.S. cancer statistics female breast cancer stat bite. Washington: US Department of Health and Human Services; 2023.
Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15:593–602.
Cao SS, Lu CT. Recent perspectives of breast cancer prognosis and predictive factors. Oncol Lett. 2016;12(5):3674–3678.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21‐gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121.
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy‐related acute myeloid leukemia: a national population‐based cohort study. J Clin Oncol. 2015;33(31):3641–3649.
Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67–75.
Pullarkat V, Slovak ML, Dagis A, Bedell V, Somlo G, Nakamura R, et al. Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Ann Oncol. 2009;20(12):2000–2006.
Shang Y, Zhou F. Current advances in immunotherapy for acute leukemia: an overview of antibody, chimeric antigen receptor, immune checkpoint, and natural killer. Front Oncol. 2019;19(9):917.
Pourhassan H, Agrawal V, Pullarkat V, Aldoss I. Positioning blinatumomab in the frontline of adult B‐cell acute lymphoblastic leukemia treatment. Front Oncol. 2023;17(13):1237031.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia‐Manero G, Daver N, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125(15):2579–2586.
Aldoss I, Stiller T, Song J, al Malki M, Ali H, Salhotra A, et al. Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia. Am J Hematol. 2017;92(2):E18–E19.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A‐rearranged or NPM1‐mutant leukaemia. Nature. 2023;615:920–924.